Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1. (currently amended) A compound of formula (I)(A):



wherein both dashed lines ~~are~~ complete a carbon-carbon double bond, or both are absent;

R_3 is H, C $_{1-6}$ alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, or amino, with the proviso that R_7 is methyl;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, and amino;

W is O-R_9, wherein R_9 is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or C $_{2-5}$ heterocyclic bivalent radical;

Y is absent, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, or C $_{1-6}$ alkoxy;

Z is C $_{2-8}$ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; and R_{15} is C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, C $_{3-7}$ cycloalkyl, or C $_{4-7}$ cycloalkenyl; and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, C_{2-5} heterocyclic radical, phenyl, and phenyl(C_{1-3} alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;
or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

2. (previously amended) A compound of claim 1, wherein Z comprises piperidyl, morpholinyl, piperazinyl, pyrrolidyl, or a C_{6-8} cycloalkylimino radical.

3. (deleted)

4. (original) A compound of claim 1, wherein W is hydroxy-substituted C_{2-4} alkoxy, C_{2-4} alkoxy, C_{2-4} alkylamino, butenyl, or butynyl.

5. (previously amended) A compound of claim 1, wherein W comprises propoxy, ethoxy, propylamino, or ethylamino.

6. (deleted)

7. (original) A compound of claim 1 wherein at least one of R_a, R_b, R_d, and R_e is methyl.

8. (currently amended) A compound of claim 1, wherein each of R_5, R_6, and R_8 is independently H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro; or wherein one of R_a, R_b, R_c, R_d, and R_e is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro~~; or both~~.

9. (original) A compound of claim 1, wherein both dashed lines are present to form two carbon-carbon double bonds.

10. (original) A compound of claim 1, wherein both dashed lines are absent.

11. (original) A compound of claim 1, wherein R_a or R_e is methyl, fluoro, or methoxy.

12. (deleted)

13. (deleted)

14. (currently amended) A compound of claim 1, wherein
R_3 is H or methyl;
each of R_b and R_d is independently H, methyl, or methoxy;
R_8 is H, methyl, fluoro, or chloro;
each of R_5 and R_6 is H;
each of R_a or R_e is independently H, methyl, fluoro, or chloro;
W is C_{2-4} alkoxy, C_4 alkylene, C_4 alkynylene, C_4 alkenylene, -$N(R_{10})SO_2$-(C_{1-5} alkyl), -(CO)O-C_{2-3} alkyl, -(CO)NH-(C_{1-3} alkyl), -NH(CO)(C_{1-3} alkyl), or -NH(C_{1-6} alkyl); and
Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, or (piperidyl)-piperidyl.

15. (deleted)

16. (previously amended) A compound of claim 2, selected from 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylaminopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine;and 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

17. (previously amended) A compound selected from 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; and 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine.

18. (original) A compound of claim 16, having the formula 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

19. (previously amended) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically-acceptable carrier.

20. (currently amended) A pharmaceutical composition of claim 19, wherein said compound has a formula wherein R_3 is H or methyl; each of R_b and R_d is independently H, methyl, or methoxy; R_8 is H, methyl, fluoro, or chloro; each of R_5 and R_6 is H; each of R_a or R_e is independently H, methyl, fluoro, or chloro; W is C_{2-4} alkoxy; and Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, or (piperidyl)-piperidyl.

21. (previously amended) A pharmaceutical composition of claim 20, wherein said compound has a formula selected from 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylaminopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; and 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine.

22. (original) A pharmaceutical composition of claim 20, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

23. (currently amended) A method for treating disorders mediated by the histamine H_3 receptor in a patient, said method comprising administering to the patient a pharmaceutically effective amount of compound of formula (I):



wherein both dashed lines ~~are~~ complete a carbon-carbon double bond, or both are absent;

R_3 is H, C $_{1-6}$ alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, and amino;

W is O-R_9, wherein R_9 is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or C $_{2-5}$ heterocyclic bivalent radical;

Y is absent, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, or C $_{1-6}$ alkoxy;

Z is C $_{2-8}$ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; and R_{15} is C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, C $_{3-7}$ cycloalkyl, or C $_{4-7}$ cycloalkenyl; and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C $_{1-3}$ alkyl, halo, hydroxy, C $_{2-5}$ heterocyclic radical, phenyl, and phenyl(C $_{1-3}$ alkyl); and wherein each of the above

heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;
or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

24. (previously amended) A method of claim 23, wherein said compound is selected from 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylaminopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 2-(4-piperidino-propoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

25. (original) A method of claim 23, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

26. (currently amended) A method for treating a patient with a central nervous system disorder, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):



wherein both dashed lines ~~are~~ complete a carbon-carbon double bond, or both are absent;

R_3 is H, C $_{1-6}$ alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, and amino;

W is O-R_9, wherein R_9 is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or C $_{2-5}$ heterocyclic bivalent radical, and R_{10} is H, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, phenyl, or C $_{2-5}$ heterocyclic radical;

Y is absent, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, or C $_{1-6}$ alkoxy;

Z is C $_{2-8}$ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; and R_{15} is C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, C $_{3-7}$ cycloalkyl, or C $_{4-7}$ cycloalkenyl;

and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C $_{1-3}$ alkyl, halo, hydroxy, C $_{2-5}$ heterocyclic radical, phenyl, and phenyl(C $_{1-3}$ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;

or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

27. (deleted)

28. (original) A method of claim 26, wherein said central nervous system disorder is selected from sleep/wake disorders, arousal/vigilance disorders, dementia, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorder, learning and memory disorders, mild cognitive impairment, and schizophrenia.

29. (original) A method of claim 26, wherein said central nervous system disorder is selected from Alzheimer's disease, epilepsy, eating disorders, learning and memory disorders, migraine, sleep/wake disorders, allergic rhinitis, schizophrenia, mild cognitive impairment, and asthma.

30. (previously amended) A method of claim 26, wherein said compound is selected from 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylaminopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 2-(4-piperidino-propoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

31. (deleted)

32. (original) A method of claim 26, wherein said disorder is selected from sleep/wake disorders, arousal/vigilance disorders, attention deficit hyperactivity disorder, and learning and memory disorders.

33. (currently amended) A method for treating a patient with an upper airway allergic response, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):



wherein both dashed lines ~~are~~ complete a carbon-carbon double bond, or both are absent;

R_3 is H, C $_{1-6}$ alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, and amino;

W is O-R_9, wherein R_9 is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or C $_{2-5}$ heterocyclic bivalent radical, and R_{10} is H, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, phenyl, or C $_{2-5}$ heterocyclic radical;

Y is absent, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, or C $_{1-6}$ alkoxy;

Z is C_{2-8} heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; and R_{15} is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, C_{3-7} cycloalkyl, or C_{4-7} cycloalkenyl;
and
each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, C_{2-5} heterocyclic radical, phenyl, and phenyl(C_{1-3} alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;
or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

34. (previously amended) A method of claim 33, wherein said compound is selected from 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylaminopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 2-(4-piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

35. (original) A method of claim 33, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.